- |||||||||| Kineret (anakinra) / SOBI
Trial completion date, Trial primary completion date: Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study (clinicaltrials.gov) - Nov 12, 2021
P2/3, N=32, Active, not recruiting,
The REDUCE trial aims to further assess the analgesic effect of single dexamethasone as an adjuvant to scalp nerve blocks for relief of postcraniotomy pain without the background of perioperative glucocorticoid. Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Jan 2022
- |||||||||| Rituxan (rituximab) / Roche
Trial completion date: A Phase II Study of the FIL on Elderly Frail Patients With DLBCL (clinicaltrials.gov) - Nov 12, 2021
P2, N=68, Active, not recruiting,
The newly customizable size and shape of the 3D printed sorbent opens new possibilities for extracting small molecules from human plasma. Trial completion date: Aug 2021 --> Dec 2021
- |||||||||| dexamethasone / Generic mfg.
Journal: Frequency and determinant factors for calcification in neurocysticercosis. (Pubmed Central) - Nov 12, 2021
Approximately 38% of parenchymal cysts calcify after antiparasitic treatment. Some factors associated to calcification are modifiable and may be approached to decrease or avoid calcification, potentially decreasing the risk for seizure relapses.
- |||||||||| budesonide / Generic mfg., bezafibrate / Generic mfg.
Clinical, Review, Journal: Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. (Pubmed Central) - Nov 12, 2021
All patients with PBC should receive initial treatment with ursodeoxycholic acid (UDCA), and odds for response are based on characteristics at baseline...Incomplete responders should be considered for second-line therapies with obeticholic acid (licensed) or fibrates (unlicensed) in addition to continued treatment with UDCA. Patients with PBC should be followed for life.
- |||||||||| dexamethasone / Generic mfg., cyclosporine / Generic mfg.
Journal: Role and expression of non-classical human leukocyte antigen-G in renal transplanted allografts. (Pubmed Central) - Nov 12, 2021
PCT in this small cohort of PIIRS was associated with improvements in CM-related complications with minimal toxicity in the acute setting. Unlike immunosuppressants, acquired HLA-G expression might confer long-term renal preservation effects in renal transplanted allografts.
- |||||||||| dexamethasone / Generic mfg.
Journal: Circadian clock gene BMAL1 controls testosterone production by regulating steroidogenesis-related gene transcription in goat Leydig cells. (Pubmed Central) - Nov 12, 2021
Additionally, real-time quantitative polymerase chain reaction (PCR) analysis revealed that the circadian clock (BMAL1, PER1, PER2, DBP, and NR1D1) and steroidogenesis-related genes (SF1, NUR77, StAR, HSD3B2, CYP17A1, CYP11A1, and HSD17B3) showed rhythmic expression patterns in goat LCs following dexamethasone synchronization...Reporter assays revealed that goat BMAL1, or in combination with mouse CLOCK, activated goat HSD17B3 transcription in vitro. These data indicate that BMAL1 contributes to testosterone production by regulating transcription of steroidogenesis-related genes in goat LCs, providing a basis for further exploring the underlying mechanism by which the circadian clock regulates ruminant reproductive capability.
- |||||||||| dexamethasone / Generic mfg.
Journal: Drug delivery in cochlear implantation. (Pubmed Central) - Nov 12, 2021
A feasibility study in human subjects with MED-EL CI featuring dexamethasone-eluting electrode array started in June 2020. This article covers the milestones of translational research towards the drug delivery in CI application that took place in association with MED-EL.
- |||||||||| hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg.
Journal, IO biomarker: Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells. (Pubmed Central) - Nov 12, 2021
Although anti-malarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ) are currently used for the treatment of systemic lupus erythematosus, their efficacy for lupus nephritis (LN) remains unclear...We then analyzed whether pretreatment with CQ, HCQ, or dexamethasone (DEX) inhibits poly IC-induced expression of these chemokines using real-time quantitative reverse transcriptase PCR and ELISA...In turn, these findings may further support the theory that the use of HCQ is safer than CQ in a clinical setting. However, further detailed studies are needed to confirm our preliminary findings.
- |||||||||| beclometasone/formoterol / Generic mfg.
Journal: Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study. (Pubmed Central) - Nov 12, 2021
In this study, we compared the lung deposition at different mean flow rates of three inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combinations delivered by dry powder inhaler (DPI), that is, Foster NEXThaler (extrafine formulation of beclomethasone/formoterol), Relvar Ellipta (fluticasone furoate/vilanterol trifenatate), and Symbicort Turbohaler (budesonide/formoterol)...NEXThaler demonstrated inspiratory flow rate independency of lung deposition versus Turbohaler. These findings suggest that the extrafine formulation is superior to large particle formulations in delivering ICS/LABA consistently both to the large and small airways.
- |||||||||| prednisolone / Generic mfg.
Journal: Henoch-Schönlein purpura: Another COVID-19 complication. (Pubmed Central) - Nov 12, 2021
In this report, we highlight a case of HSP occurring 2 days after diagnosis of COVID-19 in a 16-year-old boy, who presented with palpable purpura of the lower extremities and buttocks, diffuse abdominal pain, hemoptysis, and hematochezia. He was treated with oral prednisolone with rapid clinical improvement.
- |||||||||| triamcinolone acetonide topical / Generic mfg.
Successful treatment of pityriasis rubra pilaris with antiinflammatory mediterranean diet and low-dose vitamin A () - Nov 11, 2021 - Abstract #ISDS2021ISDS_210;
The patient was started on triamcinolone 0.1% cream, over-the-counter vitamin D, vitamin C, and probiotics without improvement 10 days later...Vitamin A levels checked at the time were within normal limits. This case highlights PRP-induced eosinophilia and is the first to note the utility of the anti-inflammatory Mediterranean diet and low-dose vitamin A for treatment of PRP.
- |||||||||| triamcinolone acetonide / Generic mfg., 5-fluorouracil / Generic mfg., tacrolimus topical / Generic mfg.
Cutaneous IgG4-related disease treated with intralesional triamcinolone acetonide and 5-fluorouracil () - Nov 11, 2021 - Abstract #ISDS2021ISDS_164;
Multiple prior treatments had been ineffective, including prednisone, radiation therapy, topical and oral dapsone, rituximab infusions, tacrolimus ointment, triamcinolone acetonide injections, and hydrocortisone ointment...Her pain completely resolved following the first injection and the plaque thinned significantly with almost complete resolution of erythema over the course of treatment. Given our patient’s significant improvement following combined intralesional injections of triamcinolone acetonide with 5-FU, further investigation is warranted into this combination as a potential treatment option for isolated or refractory cases of cutaneous IgG4-RD.
- |||||||||| hydroxychloroquine / Generic mfg.
BRAF/MEK Inhibitor Induced subacute cutaneous lupus erythematosus () - Nov 11, 2021 - Abstract #ISDS2021ISDS_154;
A 70-year-old woman with stage IV BRAF positive malignant melanoma was put on BRAF inhibitor/MEK inhibitor, dabrafenib/trametinib...Another BRAF/MEK inhibitor, encorafenib/ binimetinib was started...Moisturization and triamcinolone 0.1% ointment with impression of xerosis cutis dermatitis were ineffective...Treatment trials of 1 month doxycycline and 1 month azithromycin did not help...With impression of SCLE, started hydroxychloroquine...Our case, to our knowledge is the first reported BRAF/MEK inhibitor induced SCLE confirmed also by more specific lupus markers. The evolution of rash in post treatment period in this case demands attention to this differential diagnosis even several months after discontinuation of targeted therapy.
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Clinical, Journal: Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. (Pubmed Central) - Nov 11, 2021
The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide...Current recommendations for thromboprophylaxis suggest the use of low-dose acetylsalicylic acid in patients with low risk for thrombosis and therapeutic dose anticoagulation with LMWH or warfarin for high-risk patients...The new direct oral anticoagulants have been preliminarily evaluated for the prophylaxis of thrombotic events in IMiDs-treated myelomas, being promising, even if more expensive. Currently, the most reliable tool for a correct thrombotic risk stratification appears to be the complete clinical and anamnestic evaluation of the myeloma patients added to a strong physician awareness of the evidences that the literature contains until now.
- |||||||||| dexamethasone / Generic mfg.
Journal: Control of axillary bud growth in tobacco through toxin gene expression system. (Pubmed Central) - Nov 11, 2021
In this study, a toxin gene control system for plants based on dexamethasone (DEX) induction was constructed, and the positive transgenic tobacco exhibited growth retardation in the application area (axillary bud)...Here, a chemical induction system, combined with a toxin gene, were used to successfully control the growth of tobacco axillary buds after topping. The DTA expression system under DEX induction was sensitive and efficient, therefore, can be used to control axillary bud growth and development in tobacco.
- |||||||||| dexamethasone / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection (clinicaltrials.gov) - Nov 11, 2021
P4, N=150, Recruiting,
The DTA expression system under DEX induction was sensitive and efficient, therefore, can be used to control axillary bud growth and development in tobacco. Not yet recruiting --> Recruiting | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
- |||||||||| dexamethasone / Generic mfg.
Review, Journal: Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. (Pubmed Central) - Nov 10, 2021
Intensive research on corticosteroid therapy in COVID-19 treatment is urgently needed to elucidate their mechanisms and importance in contributing toward successful prevention and treatment approaches. Hence, this review emphasizes on recent advancement on corticosteroid therapy for defining their importance in overcoming SARS-CoV-2 pandemic, their mechanism, efficacy and extent of corticosteroids in the treatment of COVID-19 patients.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] A retrospective observational study of COVID-19 patients on a respiratory high care unit (RHCU) () - Nov 10, 2021 - Abstract #BTSWMI2021BTS_WM_I_483;
Of those eligible, 100% received dexamethasone, 95% were appropriately anticoagulated, 87% were given tocilizumab and 61% received remdesivir. 29% of patients were recruited into the RECOVERY trial, far exceeding recruitment within the trust (11.2%), regionally within the West Midlands (6.3%), and nationally (10%).
- |||||||||| hydrocortisone / Generic mfg.
[VIRTUAL] Elective inpatient systematic evaluation of difficult to treat asthma; case series demonstrating the clinical value and improved patients outcomes () - Nov 10, 2021 - Abstract #BTSWMI2021BTS_WM_I_469;
This allowed significant reduction of maintenance prednisolone dose to a mean of 5.6±2.6 mg/day ( figure 1 ) and 73% of cases were converted to replacement hydrocortisone...Conclusions In this study we observed significant benefit to patients in establishing the correct diagnosis, revision of treatment and reduction of dependency on maintenance oral corticosteroids. Research is required to define the criteria for patients who would benefit from such systematic inpatient assessment and the longterm outcomes of such intervention.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] Tick tock...where and when can we give toc? Review of COVID-19 patients receiving tocilizumab in a non critical care setting () - Nov 10, 2021 - Abstract #BTSWMI2021BTS_WM_I_456;
Introduction The REMAP-CAP trial demonstrated the positive effects of interleukin-6 receptor antagonists (tocilizumab and sarilumab), on mortality in COVID-19 patients managed in a critical care setting...Prior to January 2021 standard ward level care included IV antibiotics, IV remdesivir, oral dexamethasone and non-invasive ventilation...Conclusion This data supports the use of tocilizumab in patients with COVID-19 disease, noting its positive effect on hospital mortality for COVID-19 patients on non-invasive respiratory support but not requiring critical care. Moreover, the limited side effect profile witnessed suggests tocilizumab can be safely administered in a non-critical care setting.
- |||||||||| dexamethasone / Generic mfg.
[VIRTUAL] The impact of drug therapies on COVID-19 mortality in a UK tertiary centre () - Nov 10, 2021 - Abstract #BTSWMI2021BTS_WM_I_455;
Dexamethasone reduced the 30-day mortality, although it did not reach statistical significance, likely due to the retrospective nature and small sample size of this study. Our findings corroborate clinical trial data on the benefit of dexamethasone therapy.
|
